Matrix Attachment Regions in the Human Dystrophin Gene

Total Page:16

File Type:pdf, Size:1020Kb

Matrix Attachment Regions in the Human Dystrophin Gene MATRIX ATTACHMENT REGIONS IN THE HUMAN DYSTROPHIN GENE Stephanie Doreen Ditta A tbesis submitted in confordty witb tbe reguirements for the degree of Doctor of Pbilosophy Graduate Department of Molecular and Medical Genetics University of Toronto O Copyright by Stepbanie Doreen Ditta 200 du="-?l?na- Cana The author has granted a non- L'auteur a accordé une licence non exclusive licence dowing the exclusive permettant à la National Library of Canada to Bibliothèque nationaie du Canada de reproduce, loan, distribute or seU reproduire, prêter, distribuer ou copies of this thesis in microforni, vendre des copies de cette thése sous paper or electronic formats. la fome de microfiche/film, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neitber the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fiom it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. Math Attacbment Regions in the Human Dystrophin Gene Ph.D., 2000 Stephanie Doreen Ditta Department of Molecular and Medical Genetics University of Toronto A bstract Duchenne muscular dystrophy @MD) is a lethal degenerative muscle disorder caused by mutations in the dystrophin gene. Dystrophin is a cytoskeletal protein associated with the plasma membrane. .dystrophin gene is exceptional with mspect CO its size and complexity. It is the largest gene identified to date, containing 79 exons across 2300 kb and at least seven distinct tissue-specific promoters. This X-linked gene is characterized by a high mutation rate, with most affected individuals having chromosomal rearrangernents. Approximately 60% of males with the disease have deietions in the dysimpbin gene and 6% have duplications. In this study, the role of chmatin organization of the dystrophin gene in nuclear functions is investigated. The interactions of DNA with proteins of the nuclear rnatrix rnay be involved in such functions as defining chnimaiin loops or domains, DNA replication, transcriptional reguiation and iiiegitimate recombination. The DNA regions involved in these interactions are specific DNA sequences dedma& attachment regions (MARS). This work examines the possible involvernent of dystrophin gene MARS in both diseasecausing chromosomai rearrangements and transcriptional regulation. Specifically, points of amchment of tbe dystrophin gene to the nuclear matrix have been identifieci in this study at the breakpoints of a duplication hma DMD patient and in the muscle- specfic promoter region. MARS have been identifieci at both the intmn 7 and inîron 9 breakpoints of a dystmphin gene duplication which resulted hm a non-homologous recombination event. This hding indicates the possible positionhg of these breakpoints in close proximity to one another on the nuclear matrïx, proviiàing the opportunity for recombination to occw. Both bceakpoints contain topoisoncerase 1 consensus cleavage sites, suggesting a molecular mechanism for DNA exchange in tbis recombination event. In addition, two MARS have been found to flank the intemal muscle-specific promoter of the dystrophin gene. The proximity of these two MARS to this cis-acting mgulatory element indicates a possible role for these MARS in transcriptional replation hmthis promoter, perhaps through interactions with transcription factors on the nuclear matrix. These results suggest important des for dystrophin gene MARS in both illegitimate recombination and transcriptional regdation in this gene. iii Acknowledgements 1wodd like to thiuik the Canadian Institutes of Health Research (formerly the Medical Research Councii of Canada), tbe Ontario Graduate Scholarship Program and the Hospital for Sick Children Research Training Centre (Toronto) for the financial support of the work ptesented in this thesis. 1 acknowledge my supervisors, Drs. Ronald Worton and Peter Ray, as well as Drs. Brenda Andrews, Paul Sadowski and Lap-Chee Tsui, for serving on my supervisory cornmittee. My thanks to Dr. Arthur Roach for his guidance and support. 1am grateful to Dr. Amira Klip for her kindness, support and valuable advice. 1would like to thank my laboratory colleagues, pst and present, for their help and friendship, especiaily Ramona Cooperstock, Peny Howard, Xiuyuan Hu, Henry Klarnut and Christine Tennyson. 1also thank my friends Carol Freund, Geoff Clarke and Mandy Lowe. My very special thanks to Fîora Krasnoshtein for her constant friendship and encouragement. 1wish to thank my mother, Doreen Ditta, my sisters, Susan Lightstone, Mary Louise Diua and Joan Frawley, and my extended family rnembers for their love and support. Many thanks to my aunt, Jean Dunham, who has made my stay in Toronto enjoyable. Special thanks to my cousins, Cameron Jenkins, who first sparked my interest in genetics, and Kirnberly Gray, who remindecl me of who 1 am. 1 also th& my father, Frank L. Ditta, for al1 that he taught me so long ago. Table of Contents .. Abstract ......................................................................................................u Acknowledgements ........................................................................................iv Table of Contents ........................................................................................ v List of Figures ........................................................................................... vii Chapter 1 - Introduction Overview .................................................................................................... 2 Dystrophin .................................................................................................. -3 Duchenne and Becker Muscular Dystrophy .................................................... 3 Dystrophin Gene ................................................................................... 3 Dystrophin Structure.............................................................................. 6 Dystrophin Function .............................................................................. 8 Dystrophin Isoforms.............................................................................. 9 Matrix Attachment Regions .............................................................................. 12 Nuclear Matrix ................................................................................... -12 MAR Structure.................................................................................... 16 MARS in Replication ............................................................................ -17 MARS in Transcription .......................................................................... 18 MARS in Illegitimate Recombination .......................................................... 20 Rationale .............................................................................................. 21 MARS and Illegitirnate Recombination in the Dystrophin Gene............................ 21 MARS and Transcription in the Dystrophin Gene............................................ 22 Hypothesis ....................................................................................... -24 Chapter 2 .Partid Gene Duplication in the Dystrophin Gene due to Recombination Between Matrix Attachment Regions Abstract ..................................................................................................... 26 Introduction ............................................................................................... -27 Materials and Metbods .................................................................................... 29 Patient ............................................................................................. 29 DNA clones ....................................................................................... 30 Ce11 Culture....................................................................................... 30 in vitro DNA-Binding Assay ................................................................... 30 in vivo MAR Isolation Method ................................................................. 32 Isolation of Total Genomic DNA ............................................................... 33 Results ..................................................................................................... -34 Identification of MAR at intron 9 breakpoint ................................................. 34 Identification of MAR at intron 7 breakpoint ................................................. 40 DNA sequence-based MAR predictions ...................................................... -43 Discussion ............................................................................................. 46 Cbapter 3 .The Role of Matrix Attachment Regions in Transcriptional Regulation fmm the MusckSpecilic Promoter in the Dystrophin Gene Introduction ............................................................................................. -31 Materials and Methods .................................................................................... 53 DNA clones .......................................................................................53 Ce11 Culture ........................................................................................ 54 in vitro DNA-Binding Assay ................................................................ 54 in vivo MAR Isolation Method ................................................................
Recommended publications
  • Molecular and Cellular Biology Volume 4 - December 1984 C Number 12
    MOLECULAR AND CELLULAR BIOLOGY VOLUME 4 - DECEMBER 1984 C NUMBER 12 Aaron J. Shatkin, Editor in Chief(1985) Louis Siminovitch, Editor (1985) Roche Institute of Molecular Biology Hospital for Sick Children Nutley, N.J. Toronto, Canada Harvey F. Lodish, Editor (1986) Paul S. Sypherd, Editor (1985) Whitehead Institute for Biomedical University of California Research Irvine, Calif. Cambridge, Mass. Harold E. Varmus, Editor (1989) David J. L. Luck, Editor (1987) University of California Rockefeller University San Francisco New York, N.Y. EDITORIAL BOARD Renato Baserga (1985) Ari Helenius (1984) Steven McKnight (1986) Milton J. Schlesinger (1986) Alan Bernstein (1984) Susan A. Henry (1985) Robert L. Metzenberg (1985) Phillip A. Sharp (1985) J. Michael Bishop (1984) Ira Herskowitz (1984) Robert K. Mortimer (1985) Fred Sherman (1985) Joan Brugge (1985) James B. Hicks (1986) Paul Neiman (1986) Anna Marie Skalka (1986) Breck Byers (1985) John A. Carbon (1984) Tony Hunter (1986) Harvey L. Ozer (1985) Pamela Stanley (1985) Lawrence A. Chasin (1985) Larry Kedes (1985) Mary Lou Pardue (1985) Joan A. Steitz (1985) Nam-Hai Chua (1985) Barbara Knowles (1986) Mark Pearson (1985) James L. Van Etten (1985) Terrance G. Cooper (1984) Marilyn Kozak (1985) Jeremy Pickett-Heaps (1985) Jonathan R. Warner (1984) James E. Darnell, Jr. (1985) Monty Krieger (1986) Robert E. Pollack (1985) Robert A. Weinberg (1984) Gary Felsenfeld (1985) Elias Lazarides (1985) Keith R. Porter (1985) I. Bernard Weinstein (1985) Norton B. Gilula (1985) John B. Little (1985) John R. Pringle (1985) Harold Weintraub (1985) James E. Haber (1984) William F. Loomis, Jr. (1985) Daniel B. Rifkin (1985) Reed B.
    [Show full text]
  • Printable List of Laureates
    Laureates of the Canadian Medical Hall of Fame A E Maude Abbott MD* (1994) Connie J. Eaves PhD (2019) Albert Aguayo MD(2011) John Evans MD* (2000) Oswald Avery MD (2004) F B Ray Farquharson MD* (1998) Elizabeth Bagshaw MD* (2007) Hon. Sylvia Fedoruk MA* (2009) Sir Frederick Banting MD* (1994) William Feindel MD PhD* (2003) Henry Barnett MD* (1995) B. Brett Finlay PhD (2018) Murray Barr MD* (1998) C. Miller Fisher MD* (1998) Charles Beer PhD* (1997) James FitzGerald MD PhD* (2004) Bernard Belleau PhD* (2000) Claude Fortier MD* (1998) Philip B. Berger MD (2018) Terry Fox* (2012) Michel G. Bergeron MD (2017) Armand Frappier MD* (2012) Alan Bernstein PhD (2015) Clarke Fraser MD PhD* (2012) Charles H. Best MD PhD* (1994) Henry Friesen MD (2001) Norman Bethune MD* (1998) John Bienenstock MD (2011) G Wilfred G. Bigelow MD* (1997) William Gallie MD* (2001) Michael Bliss PhD* (2016) Jacques Genest MD* (1994) Roberta Bondar MD PhD (1998) Gustave Gingras MD* (1998) John Bradley MD* (2001) Phil Gold MD PhD (2010) Henri Breault MD* (1997) Richard G. Goldbloom MD (2017) G. Malcolm Brown PhD* (2000) Jean Gray MD (2020) John Symonds Lyon Browne MD PhD* (1994) Wilfred Grenfell MD* (1997) Alan Burton PhD* (2010) Gordon Guyatt MD (2016) C H G. Brock Chisholm MD (2019) Vladimir Hachinski MD (2018) Harvey Max Chochnov, MD PhD (2020) Antoine Hakim MD PhD (2013) Bruce Chown MD* (1995) Justice Emmett Hall* (2017) Michel Chrétien MD (2017) Judith G. Hall MD (2015) William A. Cochrane MD* (2010) Michael R. Hayden MD PhD (2017) May Cohen MD (2016) Donald O.
    [Show full text]
  • Front Matter
    MOLECULAR AND CELLULAR BIOLOGY VOLUME 3 * NUMBER 12 * DECEMBER 1983 Aaron J. Shatkin, Editor in Chief (1985) Roche Institute of Molecular Biology Nutley, N.J. Harvey F. Lodish, Editor (1986) Louis Siminovitch, Editor (1985) Massachusetts Institute of Technology Hospital for Sick Children Cambridge, Mass. Toronto, Canada David J. L. Luck, Editor (1987) Paul S. Sypherd, Editor (1985) Rockefeller University University of California New York, N.Y. Irvine, Calif. EDITORIAL BOARD Renato Baserga (1985) Ira Herskowitz (1984) Daniel B. Rifkin (1985) Alan Bernstein (1984) Larry Kedes (1985) Robert G. Roeder (1985) J. Michael Bishop (1984) Marilyn Kozak (1985) James E. Rothman (1984) Joan Brugge (1985) Elias Lazarides (1985) Phillip A. Sharp (1985) Breck Byers (1985) John B. Little (1985) Fred Sherman (1985) John A. Carbon (1984) William F. Loomis, Jr. (1985) Pamela Stanley (1985) Lawrence A. Chasin (1985) Paul T. Magee (1985) Joan A. Steitz (1985) Nam-Hai Chua (1985) Robert L. Metzenberg (1985) James L. Van Etten (1985) Terrance G. Cooper (1984) Robert K. Mortimer (1985) Jonathan R. Warner (1984) James E. Darneil, Jr. (1985) Harvey L. Ozer (1985) Robert A. Weinberg (1984) Gary Felsenfeld (1985) Mary Lou Pardue (1985) I. Bernard Weinstein (1985) Norton B. Gilula (1985) Mark Pearson (1985) Harold Weintraub (1985) James E. Haber (1984) Jeremy Pickett-Heaps (1985) Reed B. Wickner (1985) Benjamin Hall (1985) Robert E. Pollack (1985) Leslie Wilson (1985) Ari Helenius (1984) Keith R. Porter (1985) Edward Ziff (1985) Susan A. Henry (1985) John R. Pringle (1985) Helen R. Whiteley, Chairman, Publications Board Walter G. Peter Ill, Director, Publications Linda M. Illig, Managing Editor, Journals Eleanor S.
    [Show full text]
  • 75 Inter-Council Human Genome Advisory Committe 1991.Pdf (1.3MB)
    The Granting Councils: Medical Research Council, Natural Sciences and Engineering Research Council and Social Sciences and Humanities Research Council and The Secretary to the Advisory Committee: Dr. Lewis Slotin Medical Research Council i SUMMARY AND RECOMMENDATIONS The InterCouncil Genome Advisory Committee (see Note 1) recommends the immediate creation of a Genome Program in Canada. The Program would address what we do not know - but must know - about the way genomes are constructed; and how that explains organisms such as a bacterium, a yeast culture, a crop, or a human being. It would allow us to understand the significance of variation (mutation) in genomes of individuals within a species and between species. The gathering of data on genomic (DNA) sequences and on the physical relationship between them on chromosomes (gene maps) is a form of exploration (and taxonomy) familiar to the biological sciences and human enquiry. The approach is the program. Genomics is not "big science" except in concept and scope; it is a "cottage industry" involving many individuals, teams and institution. At the same time, it is an international enterprise. It would not be expensive by comparison with similar programs in other countries or with other programs in science. Canadian society can afford a genome program because it will deliver a product necessary for the future of biological (and medical) science, it will generate human resources to participate in that science, and it is likely to spawn new technologies and industries related to research on genes and the development and applications of the corresponding knowledge. A social invention, (acceptance of genetics in society), is a necessary component of a genome program in Canada.
    [Show full text]
  • University of Toronto Medical Journal University of Toronto a Student-Run Scientific Publication
    UTMJ UTMJ University of Toronto Medical Journal DECEMBER 2000 Volume 78, Number 1/December, 2000 A student-run scientific publication. Established in 1923. 4 Letter to Patrons 26 Clinicopathological Correlation 5 Preface 38 News and Views 8 Patients with Facial Difference: Assessment of 58 Morning Report Information and Psychosocial Support Needs Karen M. Horton, Lorna Renooy and Christopher R. Forrest 63 Quick Diagnosis 14 Dystrophinopathies and Nondystrophinopathies: 68 Technology Review From Molecular Biology to Clinical Diagnosis Lorraine V. Hajdur and Suneil K. Kalia 71 Historical Review VOLUME 78 / No 1 22 Phantom Menace: The Mystery of Phantom Limb Pain: 73 Book Reviews A Case Report and Review of the Literature Sonja Alexandra McVeigh 81 Crossword www.utmj.org An excellent routetoreach Healthcare your patients’lipid targets Pharmaceuticals Life-Saving Plasma Products Choose Equipment and Products first! to Diagnose Human Health In achieving effective lipid control, many delays may prevent you from reaching your targets. LIPITOR lane Possible delays ahead clear ahead NewNew clinicalclinical datadata New data1 showed LIPITOR actually gets patients to tar- get§ with fewer titrations and fewer repeat visits than Zocor ®, Mevacor ®, or Lescol®. Give your new statin patients the benefits of LIPI- Exceptional LDL-C reductions – 39-60% over the full dose range2 Significantly better LDL-C and TC/HDL-C ratio reductions, compared to Zocor or Pravachol® at starting doses3,4,5∞‡ The added benefit of excellent TG reductions – 19-37% over the full dose range2 Priced to be competitive – LIPITOR costs less than Zocor or Pravachol at usual starting doses6 An excellent first choice when you choose statintherapy.
    [Show full text]
  • Sally Thorne May 14-16, 2014 [email protected]
    HEALTH MATTERS Volume 2 ; I s s u e 6 ; J u n e 2 0 1 4 Spotlight Welcome to the CAHS Newsletter, your source for updates on activities of the Canadian Academy Forum & Annual Meeting of Health Sciences. Regional Meeting Update Visit us on the web at http://cahs-acss.ca Strategic Directions Assessment News Member News PRESIDENT’S MESSAGE Important Dates The CAHS Annual Meeting will be held in Ottawa on September 18 and 19, 2014 (details below). The annual meeting is the year’s highlight for CAHS, an opportunity for reconnecting with Fellows from across the With this edition of Health country, welcoming new Fellows into the Academy, participating in the Matters, we have been able annual Forum and hearing presentations from Fellows being recognized to follow through with our in various ways for their outstanding scholarship and important commitment to a bilingual contributions. format. As we continue to develop the potential of this newsletter, and our broader This year’s Forum, on September 18, is entitled Commercialization of communications strategy, we Health Research for Health, Social and Economic Benefit. Rick Riopelle continue to welcome ideas of McGill University and Cy Frank of University of Calgary are co- and suggestions from our chairing an outstanding planning committee who are putting together Fellows as to how we can do an exciting and stimulating program. We will also be joined by guests better with inclusivity and from industry, government and NGOs, adding variety and zest to the event. I urge you to register relevant information. early. In this Again this year, the CAHS is hosting an annual meeting with stellar speakers, opportunities for edition, engaging interchange and plenty of time for the enjoyment of the company of CAHS Fellows from you will notice a across the country.
    [Show full text]
  • Founding a New Field Largely Because They Were Capable of Observing and Appreciating the Importance of Completely Unexpected Findings
    BOOK REVIEW Founding a new field largely because they were capable of observing and appreciating the importance of completely unexpected findings. The ability to notice Dreams & Due Diligence: Till and and pursue the unanticipated result is key to both excellent science McCulloch’s Stem Cell Discovery and clinical care. and Legacy Sornberger is a writer, not a critical scientist, so readers will not gain much insight into the history of the study of hematopoieisis before Joe Sornberger and after Till’s and McCulloch’s seminal finding. And there is a bit University of Toronto Press, 2011 of Canadiocentric chauvinism expressed in the pages. For example, Ronald Worton, former Scientific Director of the Ottawa Health 184 pp., hardcover, $29.95 Research Institute, is a splendid geneticist and a major contributor to ISBN: 1442644850 inherited muscular diseases, but he is not the discoverer of the mus- cular dystrophy–associated gene, as Sornberger seems to suggest. It Reviewed by David Nathan is strange that he does not mention that Louis Kunkel of Children’s Hospital in Boston and his colleagues made key contributions to that discovery. Tak Mak of Toronto is an outstanding molecular biologist, Joe Sornberger is a professional writer commissioned by the Canadian but not the discoverer of the T cell receptor. But this criticism might be Stem Cell Foundation to create a monograph on the Canadian leg- considered caviling. The fact is that the students of Till and McCulloch acy of the collaborative efforts of James Till and the late Ernest ‘Bun’ are highly distinguished members of the scientific, and particularly McCulloch, whose seminal work was the discovery of a mouse bone hematologic, communities.
    [Show full text]
  • 2020 Spotlight Newsletter of FCIHR
    2020 Spotlight on FCIHR December 2020 No. XI Participants in the Virtual Launch of the 2020 Friesen Prize Program October 6, 2020 – “Health Research Funding in a Post-COVID-19 World” Left to Right: Her Excellency Janice Charette, High Commissioner of Canada in UK; Principal Nathalie Des Rosiers, Massey College; Dr. Aubie Angel, President, FCIHR; Dr. Mona Nemer, Chief Science Advisor of Canada; Dr. Michael Strong, President, CIHR; Dr. Rémi Quirion, Chief Scientist of Québec, FRQ-S, and Prof. Santa Ono, President, University of British Columbia (UBC) PRESIDENT’S MESSAGE We are in the midst of a brutal pandemic and 2020 will be remembered because of the rampaging disruption of COVID-19. While the prospect of effective vaccines is promising, at this writing, rates of infection and its consequences continue to increase unremittingly. In March 2020, we were advised that Massey College at the University of Toronto would close and that Sir Mark Walport Dr. Henry Friesen access to our office would be severely limited. While administrative management of our affairs were 2020 Friesen Prizewinner Distinguished Prof. Emeritus Past Chief Executive, UKRI University of Manitoba addressed, programmatic activities were disrupted. A number of sponsoring institutions cancelled in-person London, UK, thanks to Her Excellency Janice events and indicated a preference for virtual lectures, Charette. With Canada House as a setting, Sir Mark given the circumstances. As a result, Prof. Bartha gave a videorecorded Keynote address on health Knoppers’ (2019 FP) planned Western Canadian research priorities in the post-COVID-19 world. Tour to four university centres (U Calgary, U Alberta, U Manitoba, UBC) was cancelled and may not be On October 6, 2020, the International Virtual Launch reinstituted in the year to come.
    [Show full text]
  • CMHF Laureate Biography
    Ronald Worton, PhD Described as a “role model of one who has achieved success without either aggression or self- promotion” and “who brings to every interaction kindness, selflessness, consideration and empathy,” Dr. Worton stands out as both a scholar and a gentleman. Through a novel and ground breaking approach at a time when disease-gene discovery was in its infancy, Dr. Worton and his team identified the dystrophin gene which is mutated in Duchenne muscular dystrophy. This was the first gene to be identified by “positional cloning” without prior knowledge of the altered protein and provided proof-of- principle for the human genome project. His work enabled definitive diagnosis and prognosis, a clear path to potential therapy and prevention through genetic counselling and prenatal diagnosis, and was pivotal in enabling identification of other genes responsible for other forms of muscular dystrophy. Dr. Worton earned his Bachelor and Master of Science degrees, both in physics, from the University of Manitoba in 1964 and 1965. He then moved to the University of Toronto where he obtained his PhD in Medical Biophysics in 1969 under the guidance of Drs. James Till and Ernest McCulloch. He developed his interest in genetics during his postdoctoral fellowship at Yale University and then joined the Department of Genetics at The Hospital for Sick Children (SickKids) in Toronto as Director of the Cytogenetics Laboratory in 1971. In 1985 he began a ten year term as Geneticist-in-Chief at the hospital, during which time his genetics department led the world with the discovery of genes responsible for muscular dystrophy (Worton and Ray), cystic fibrosis (Tsui), Wilson’s disease (Cox), Tay-Sachs disease (Gravel) and Fanconi anemia (Buchwald).
    [Show full text]